OverviewSuggest Edit

Immutep (formerly Prima BioMed) is a biotechnology company focused on developing autoimmune and cancer immunotherapy treatment. It develops therapeutics that modulate lymphocyte activation gene-3, a cell surface molecule that plays a role in regulating T cells.
TypePublic
Founded2001
HQSydney, AU
Websiteimmutep.com

Latest Updates

Employees (est.) (Jun 2019)24(-27%)
Share Price (Jun 2021)$5(-1%)
Cybersecurity ratingAMore

Key People/Management at Immutep

Marc Voigt

Marc Voigt

Executive Director & Chief Executive Officer (CEO)
Deanne Miller

Deanne Miller

Chief Operating Officer, General Counsel & Company Secretary
Christian Mueller

Christian Mueller

Vice President Strategic Development
James Flinn

James Flinn

Intellectual Property and Innovation Director
David Fang

David Fang

Finance Director & Assistant Company Secretary
Claudia Jacoby

Claudia Jacoby

Director of Manufacturing
Show more

Immutep Office Locations

Immutep has offices in Sydney, The Rocks, Orsay, Berlin and in 1 other location
Sydney, AU (HQ)
level 12/95 Pitt St
Sydney, AU
1 Martin Pl
The Rocks, AU
225 George St
Orsay, FR
2 Rue Jean Rostand
Berlin, DE
Glinkastraße 28
Leipzig, DE
Deutscher Pl. 5A
Show all (6)

Immutep Financials and Metrics

Immutep Revenue

Market capitalization (4-Jun-2021)

323.7m

Closing stock price (4-Jun-2021)

5.0
Immutep's current market capitalization is $323.7 m.
Show all financial metrics

Immutep Cybersecurity Score

Cybersecurity ratingPremium dataset

A

94/100

SecurityScorecard logo

Immutep Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

30-39

out of 100

CSRHub logo

Immutep Online and Social Media Presence

Embed Graph

Immutep News and Updates

Immutep Reports Positive Final Data from the INSIGHT-004 Phase I Study of LAG-3 Therapy, Efti, at ASCO 2021

SYDNEY, AUSTRALIA, June 04, 2021 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, announces encouraging final data from its Phase I INSIGHT-…

Immutep Secures Second European Patent For Eftilagimod Alpha, A Soluble LAG-3 Protein, In Combination With A PD-1 Pathway Inhibitor

SYDNEY, AUSTRALIA, June 02, 2021 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, is pleased to announce the grant of patent number EP3473263 entitled “Co…

Immutep Enters Into A New Collaboration With Merck KGaA, Darmstadt, Germany For LAG-3 Therapy, Efti

SYDNEY, AUSTRALIA , June 01, 2021 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, announces a new collaboration and supply agreement with Merck KGaA , Da…

Immutep Granted Chinese Patent For Eftilagimod Alpha In Chemo-Immunotherapy Combination

SYDNEY, AUSTRALIA, May 26, 2021 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, is pleased to announce the grant of a new patent (number ZL201480073584.3…

Immutep To Present At The Jefferies Virtual Healthcare Conference

SYDNEY, AUSTRALIA, May 25, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, announced today that Immutep CEO Marc Voigt has been invited to participat…

Immutep Announces Publication of TACTI-002 and INSIGHT-004 Abstracts for ASCO 2021 Annual Meeting

SYDNEY, AUSTRALIA, May 20, 2021 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce that data from its TACTI-002 and INS…
Show more

Immutep Frequently Asked Questions

  • When was Immutep founded?

    Immutep was founded in 2001.

  • Who are Immutep key executives?

    Immutep's key executives are Marc Voigt, Deanne Miller and Christian Mueller.

  • How many employees does Immutep have?

    Immutep has 24 employees.

  • Who are Immutep competitors?

    Competitors of Immutep include Numab, Cybrexa Therapeutics and Bexion Pharmaceuticals.

  • Where is Immutep headquarters?

    Immutep headquarters is located at level 12/95 Pitt St, Sydney.

  • Where are Immutep offices?

    Immutep has offices in Sydney, The Rocks, Orsay, Berlin and in 1 other location.

  • How many offices does Immutep have?

    Immutep has 6 offices.